[
  {
    "ts": null,
    "headline": "Incyte Announces Additional FDA Approval of Opzelura速 (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis",
    "summary": "WILMINGTON, Del., September 18, 2025--Incyte Announces Additional FDA Approval of Opzelura速 (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis",
    "url": "https://finnhub.io/api/news?id=fe99e6b22d42ac68bb0aea3900f9c8d1e929b8e67b42a473fc7eb92b252bd364",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758230460,
      "headline": "Incyte Announces Additional FDA Approval of Opzelura速 (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis",
      "id": 136818800,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., September 18, 2025--Incyte Announces Additional FDA Approval of Opzelura速 (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis",
      "url": "https://finnhub.io/api/news?id=fe99e6b22d42ac68bb0aea3900f9c8d1e929b8e67b42a473fc7eb92b252bd364"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Gets FDA Approval for Dermatitis Cream for Young Children",
    "summary": "Incyte Gets FDA Approval for Dermatitis Cream for Young Children",
    "url": "https://finnhub.io/api/news?id=8684e876654c71b59be33b5e63a49f664f3786579496e45d70f61f7f04d57fb5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758213360,
      "headline": "Incyte Gets FDA Approval for Dermatitis Cream for Young Children",
      "id": 137153474,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Gets FDA Approval for Dermatitis Cream for Young Children",
      "url": "https://finnhub.io/api/news?id=8684e876654c71b59be33b5e63a49f664f3786579496e45d70f61f7f04d57fb5"
    }
  }
]